T-cell immunotherapy company Anocca AB reported on Wednesday the receipt of USD47m from its Series B financing led by Danske Bank, Swedbank Robur Ny Teknik, Ramsbury Invest.
This Series B financing was also led by significant family offices including Harald Mix, Robert Andreen, Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano.
The funds will be used to further advance Anocca AB's industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials. Its highly industrialised cellular biology platform replicates human T-cell biology in the laboratory, to generate targeted T-cell therapies with broad applicability in oncology, infectious diseases and autoimmune disorders.
According to the company, its platform has delivered a broad pipeline of T-cell receptor (TCR) assets to generate novel TCR-modified T-cell therapies (TCR-T) against multiple antigen classes. TCR-T cellular therapies can unlock an immense target space inaccessible to biologics and CAR-T therapies and is emerging as an important treatment modality for many forms of cancer.
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Flamingo Therapeutics names new director
Merck reports lung cancer trial failed to meet endpoints
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886
University of Saskatchewan Partners with SOPHiA GENETICS in landmark ovarian cancer trial